Identification of DHBcAg as a potent carrier protein comparable to KLH for augmenting MUC1 antigenicity

Vaccine

Volumn 23, Issue 39, 2005, Pages 4727-4733

  Gathuru, John K ^a   Koide, Fusataka ^a   Ragupathi, Govind ^a   Adams, Janet L ^b   Kerns, Robnet T ^b   Coleman, Timothy P ^b,c   Livingston, Philip O ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b Pricewaterhouse Coopers LLP   (United States)

^c VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer vaccine; Carrier protein; DHBcAg

Indexed keywords

CANCER VACCINE; CARRIER PROTEIN; HEPATITIS B ANTIGEN; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; KEYHOLE LIMPET HEMOCYANIN; MUCIN 1; QS 21; RECOMBINANT PROTEIN; SAPONIN; CA 15-3 ANTIGEN; COMPLEMENT; HEMOCYANIN; HEPATITIS B CORE ANTIGEN; IMMUNOLOGICAL ADJUVANT; KEYHOLE-LIMPET HEMOCYANIN; VACCINE;

ANIMAL EXPERIMENT; ANTIBODY TITER; ANTIGENICITY; ARTICLE; CELL SURFACE; CONTROLLED STUDY; FEMALE; HEPATITIS B VIRUS; HUMAN; HUMAN CELL; IMMUNIZATION; IMMUNOGENICITY; METASTASIS; MOLECULAR WEIGHT; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; AMINO ACID SEQUENCE; ANIMAL; COMPARATIVE STUDY; CYTOTOXICITY; IMMUNOLOGY; MOLECULAR GENETICS; PHYSIOLOGY;

ADJUVANTS, IMMUNOLOGIC; AMINO ACID SEQUENCE; ANIMALS; CA-15-3 ANTIGEN; CANCER VACCINES; COMPLEMENT SYSTEM PROTEINS; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; HEMOCYANIN; HEPATITIS B CORE ANTIGENS; HEPATITIS B VIRUS, DUCK; IMMUNIZATION; MICE; MOLECULAR SEQUENCE DATA; VACCINES, CONJUGATE;

EID: 25144487773     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2005.05.007     Document Type: Article

References (34)

1. Hakomori S-I. Tumor malignancy defined by aberrant glycosylation and sphingo(glyco)lipid metabolism. Can Res 1996;56:5309-18.
2. Lloyd KO. Blood group antigens as markers for normal differentiation and malignant changes in human tissues. Am J Clin Pathol 1987;87:129-39.
3. Zhang S, Zhang HS, Cordon-Cardo C, Ragupathi G, Livingston PO. Selection of tumor antigens as targets for immune attack using immunohistochemistry: III protein antigens. Clin Cancer Res 1998;4:2669-76.
4. Zotter S, Hageman PC, Lossnitzer A. Tissue and tumor distribution of human polymorphic epithelial mucin. Cancer Rev 1988;11:55-101.
5. Gendler SJ, Lancaster CA, Taylor-Papadimitriou J, Duhig T, Peat N, Burchell J, et al. Molecular cloning and expression of human tumor-associated polymorphic epithelial mucin. J Biol Chem 1990;265:15286-93.
6. Gendler S, Taylor-Papadimitriou J, Duhig T, Rothbard J, Burchell J. A highly immunogenic region of a human polymorphic epithelial mucin expressed by carcinomas is made up of tandem repeats. J Biol Chem 1988;263:12820-3.
7. Lloyd KO, Burchell J, Kudryashov V, Yin BWT, Taylor-Papadimitriou J. Comparison of O-linked carbohydrate chains in MUC1 mucin from normal breast epithelial cell lines and breast carcinoma cell lines. J Biol Chem 1996;271:33325-34.
8. Burchell J, Taylor-Papadimitriou J, Boshell M, Gendler S, Duhig T. A short sequence, within the amino acid tandem repeat of a cancer-associated mucin, contains immunodominant epitopes. Int J Cancer 1989;44:691-6.
9. Livingston PO, Calves MJ, Helling F, Zollinger WD, Blake MS, Lowell GH. GD3/proteosome vaccines induce consistent IgM antibodies against the ganglioside GD3. Vaccine 1993;11:1199-204.
10. Livingston PO, Natoli Jr EJ, Jones Calves M, Stockert E, Oettgen HF, Old LJ. Vaccines containing purified GM2 ganglioside elicit GM2 antibodies in melanoma patients. Proc Natl Acad Sci USA 1987;84:2911-5.
11. Helling F, Shang Y, Calves M, Oettgen HF, Livingston PO. Increased immunogenicity of GD3 conjugate vaccines: comparison of various carrier proteins and selection of GD3-KLH for further testing. Cancer Res 1994;54:197-203.
12. Kim S-K, Ragupathi G, Musselli C, Livingston PO. Comparison of the effect of different immunological adjuvants on the antibody and T cell response to immunization with MUC1-KLH and GD3-KLH conjugate vaccines. Vaccine 1999;18:597-603.
13. Kim S-K, Ragupathi G, Cappello S, Kagan E, Livingston PO. Effect of immunological adjuvant combinations on the antibody and T-cell response to vaccination with MUC1-KLH and GD3-KLH conjugates. Vaccine 2000;19:530-7.
14. Zhang S, Walberg LA, Helling F, Ragupathi G, Adluri S, Lloyd KO, et al. Augmenting the immunogenicity of synthetic MUC-1 vaccines in mice. Cancer Res 1996;55:3364-8.
15. Gilewski T, Adluri S, Zhang S, Ragupathi G, Houghton A, Norton L, et al. Vaccination of high risk breast cancer patients with Mucin-1 keyhole limpet hemocyanin conjugate plus QS-21. Clin Cancer Res 2000;6:1693-701.
16. Gilewski T, Ragupathi G, Bhuta S, Williams LJ, Musselli C, Zhang XF, et al. Immunization of metastatic breast cancer patients with a fully synthetic globo H conjugate: a phase I trial. Proc Natl Acad Sci USA 2001;98:3270-5.
17. Chapman PB, Morrisey D, Panageas KS, Williams L, Lewis JJ, Israel RJ, et al. Vaccination with a bivalent GM2 and GD2 ganglioside conjugate vaccine: A trial comparing doses of GD2-KLH. Clin Cancer Res 2000;6:4658-62.
18. Schodel F, Peterson D, Hughes J, Milich D. Hepatitis B virus core particles as a vaccine carrier moiety. Int Rev Immunol 1994;II:153-65.
19. Schodel F, Moriarty AM, Peterson DL, Zheng JA, Hughes JL, Will H, et al. The position of heterologous epitopes inserted in hepatitis B virus core particles determines their immunogenicity. J Virol 1992;66:106-14.
20. Schodel F, Peterson D, Hughes J, Milich D. Avirulent salmonella expressing hybrid hepatitis B virus core/preS genes for oral vaccine. Vaccine 1993;11:143-8.
21. Schodel F, Peterson D, Zheng J, Jones J, Hughes J, Milich D. Structure of hepatitis B virus core and E antigens: a single pre-core amino acid prevents nucleocapsid assembly. J Biol Chem 1993;268(2):1332-7.
22. Milich D, Peterson D, Zheng J, Hughes J, Wirtz R, Schodel F. The hepatitis nucleocapsid as a vaccine carrier moiety. Ann NY Acad Sci 1995;754:187-201.
23. Schodel F, Peterson D, Hughes J, Wirtz R, Milich D. Hybrid hepatitis B virus core antigen as a vaccine carrier moiety: I. presentation of foreign epitopes. J Biotechnol 1996;44(1-3):91-6.
24. Paoletti LC, Peterson DL, Legmann R, Collier RJ. Preclinical evaluation of group B streptococcal polysaccharide conjugate vaccines prepared with a modified diphtheria toxin and a recombinant duck hepatitis B core antigen. Vaccine 2001;20:370-6.
25. Zheng J, Schodel F, Peterson DL. The structure of hepadnaviral core antigens. Identification of free thiols and determination of the disulfide bonding pattern. J Biol Chem 1992;267:9422-9.
26. Ragupathi G, Cappello S, Yi SS, Canter D, Spassova M, Bormann WG, et al. Comparison of antibody titers after immunization with monovalent or tetravalent KLH conjugate vaccines. Vaccine 2002;20:1030-8.
27. Helling F, Zhang S, Shang A, Adluri S, Calves M, Koganty R, et al. GM2-KLH conjugate vaccine: increased immunogenicity in melanoma patients after administration with immunological adjuvant QS-21. Cancer 1995:2783-8.
28. Wynne SA, Crowther RA, Leslie AGW. The crystal structure of the human hepatitis B virus capsid. Mol Cell 1999;3:771-80.
29. Bringas R. Folding and assembly of hepatitis B virus core protein: a new model proposal. J Struct Biol 1997;118:189-96.
30. Crowther RA, Kiselev NA, Bötcher B, Berriman JA, Borisova GP, Ose V, et al. Three-dimensional structure of hepatitis B virus core particles determined by cryomicroscopy. Cell 1994;77:943-50.
31. Kenney JM, von Bonsdorff CH, Nassal M, Fuller SD. Evolutionary conservation in the hepatitis B core structure: comparison of human and duck cores. Structure 1995;3:1009-19.
32. Lobaina Y, Garcia D, Abreu N, Muzio V, Aguilar JC. Mucosal immunogenicity of the hepatitis B core antigen. Biochem Biophys Res Commun 2002;300:745-50.
33. Lazdina U, Cao T, Steinbergs J, Alheim M, Pumpens P, Peterson DL, et al. Molecular basis for the interaction of the hepatitis B virus core antigen with the surface immunoglobulin receptors on naïve B cells. J Virol 2001;75:6367-74.
34. Milich DR, McLachlan A. The nucleocapsid of hepatitis B virus is both a T-cell-independent and T-cell-dependent antigen. Science 1986;234:1398-401.